← All trials
NCT02736812
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2016
- Primary completion
- Nov 1, 2018
- Completion date
- Dec 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- French Defence Health ServiceLead sponsor
- French MilitaryCollaborator
- Fire Brigade Of ParisOverall official - principal investigator
- Fire Brigade Of ParisReponsible party - principal investigator
- Bataillon des marins pompiers de Marseille, FranceCollaborator
- Samu of Lyon, FranceCollaborator
- Hospital center of Annecy Genevois,FranceCollaborator
- Institut de Recherche Biomedicale des ArmeesCollaborator
- Samu of Annecy, FranceCollaborator
- University of LyonCollaborator
- Aix-University of MarseilleCollaborator
- CHU Henri MondorCollaborator
- Fire Brigade Of ParisCollaborator
- University of ParisCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.